KR20180033781A - Method of producing a food for preventing and improving diabetes - Google Patents
Method of producing a food for preventing and improving diabetes Download PDFInfo
- Publication number
- KR20180033781A KR20180033781A KR1020160123163A KR20160123163A KR20180033781A KR 20180033781 A KR20180033781 A KR 20180033781A KR 1020160123163 A KR1020160123163 A KR 1020160123163A KR 20160123163 A KR20160123163 A KR 20160123163A KR 20180033781 A KR20180033781 A KR 20180033781A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- food
- diabetes
- brown rice
- filtrate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 235000013305 food Nutrition 0.000 title abstract description 54
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 45
- 235000021329 brown rice Nutrition 0.000 claims abstract description 36
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 29
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 29
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 29
- 241000018646 Pinus brutia Species 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims abstract description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000003809 water extraction Methods 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 244000291564 Allium cepa Species 0.000 claims abstract 2
- 230000036541 health Effects 0.000 claims description 30
- 235000013336 milk Nutrition 0.000 claims description 21
- 210000004080 milk Anatomy 0.000 claims description 21
- 239000008267 milk Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 241001105098 Angelica keiskei Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 240000006108 Allium ampeloprasum Species 0.000 claims description 2
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 241001107116 Castanospermum australe Species 0.000 abstract description 5
- 235000008708 Morus alba Nutrition 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract description 5
- 235000021279 black bean Nutrition 0.000 abstract description 5
- 240000001810 Angelica gigas Species 0.000 abstract description 4
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 240000000249 Morus alba Species 0.000 abstract description 3
- 244000273928 Zingiber officinale Species 0.000 abstract description 3
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 3
- 235000008397 ginger Nutrition 0.000 abstract description 3
- 241000320380 Silybum Species 0.000 abstract description 2
- 235000010841 Silybum marianum Nutrition 0.000 abstract description 2
- 235000007215 black sesame Nutrition 0.000 abstract description 2
- 235000005903 Dioscorea Nutrition 0.000 abstract 1
- 244000281702 Dioscorea villosa Species 0.000 abstract 1
- 235000000504 Dioscorea villosa Nutrition 0.000 abstract 1
- 244000302512 Momordica charantia Species 0.000 abstract 1
- 235000009811 Momordica charantia Nutrition 0.000 abstract 1
- 235000004879 dioscorea Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 49
- 239000002994 raw material Substances 0.000 description 47
- 239000008280 blood Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 33
- 241000234282 Allium Species 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- 240000002045 Guettarda speciosa Species 0.000 description 20
- 235000001287 Guettarda speciosa Nutrition 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 235000020805 dietary restrictions Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 7
- 229960004245 silymarin Drugs 0.000 description 7
- 235000017700 silymarin Nutrition 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000010030 glucose lowering effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 229940008075 allyl sulfide Drugs 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000004531 blood pressure lowering effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 240000000982 Malva neglecta Species 0.000 description 2
- 235000000060 Malva neglecta Nutrition 0.000 description 2
- 241000218213 Morus <angiosperm> Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241001094255 Elytraria Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000797947 Paria Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- -1 carantine Chemical compound 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- QAMPNIXQLSTWGU-UHFFFAOYSA-M propyl sulfite Chemical compound CCCOS([O-])=O QAMPNIXQLSTWGU-UHFFFAOYSA-M 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 당뇨 예방 및 개선용 식품의 제조방법에 관한 것으로서, 보다 상세하게는 현대인들에게 빈번히 발생하는 당뇨를 인체에 부작용 없이 예방 및 개선할 수 있도록 하며, 다양한 제형으로 형성하여 범용성(凡用性)을 증대시킬 수 있는 당뇨 예방 및 개선용 식품의 제조방법에 관한 것이다.More particularly, the present invention relates to a method for preventing or ameliorating diabetes mellitus, which is frequently occurred in modern people, without adverse effects on the human body, The present invention also relates to a method for producing a food for preventing and improving diabetes.
당뇨병은 가장 일반적이고 중대한 생활습관병으로 전세계적으로 약 100만명 이상의 환자가 있는 것으로 알려져 있다. 나아가 혈당치(血糖値)가 당뇨병 수준에 미치지는 않지만 정상인들에 비하면 혈당치가 높아 관리를 요하는 사람, 소위 예비환자로 불리는 사람들의 수는 당뇨병 환자의 수를 훨씬 웃돌고 있는 실정이다.Diabetes is the most common and serious lifestyle disease, with over one million patients worldwide. Furthermore, although the blood glucose level (blood sugar level) does not reach the diabetic level, the number of people called for maintenance, the so-called prospective patient, is higher than the number of diabetics because the blood glucose level is higher than that of normal people.
한편, 당뇨병에는 인슐린(insulin)의 분비부전(分泌不全)에 의한 제Ⅰ형 당뇨병(인슐린 의존성 당뇨병)과 인슐린에 대한 감수성(感受性)의 저하에 의한 제Ⅱ형 당뇨병(인슐린 비의존성 당뇨병)이 알려져 있다. 당뇨병 환자의 대부분은 제Ⅱ형 당뇨병으로, 이 타입의 당뇨병은 과식 등 적절치 못한 생활습관에 의해 발증(發症)되는 경우가 상당하다.On the other hand, diabetes is known to have Type I diabetes (insulin-dependent diabetes) due to insulin secretion deficiency (insulin-dependent diabetes) and type II diabetes (insulin-independent diabetes) due to a decrease in insulin sensitivity have. Most of the diabetic patients are type Ⅱ diabetes, and this type of diabetes is often caused by inappropriate lifestyle such as overeating.
이와 같이 당뇨병의 문제점은 고혈압에 의한 자각증상이 거의 없기 때문에 장기적인 혈당 콘트롤이 비교적 어렵고, 이에 의해 다양한 합병증(망막증, 신증, 동맥경화 등)을 유발한다. 예컨대, 일본에서는 성인이 된 후의 시력장애를 유발하는 원인질환 중 1위가 당뇨병성 망막증이고, 만성신부전에 의한 인공투석에 이르는 원인질환 중 2위가 당뇨병성 신증(腎症)이다.As such, the problem of diabetes is that it is relatively difficult to control blood sugar for a long time because there are few subjective symptoms due to hypertension, thereby causing various complications (retinopathy, nephropathy, arteriosclerosis, etc.). For example, in Japan, diabetic retinopathy is the first leading cause of visual disturbance after becoming an adult, and diabetic nephropathy is the second leading cause of artificial dialysis due to chronic renal failure.
이 같이 당뇨병은 심각한 합병증을 유발한다는 점에서 당뇨병 치료의 가장 큰 목적은 철저한 혈당 콘트롤의 관리로 되고 있다. 제Ⅰ형 당뇨병 환자의 혈당 콘트롤에 대해서는 인슐린의 분비부전이 원인인 점에서 인슐린 주사가 절대적인 효과를 갖지만, 제Ⅱ형 당뇨병 환자에 대해서는 인슐린에 대한 감수성이 저하되어 있기 때문에 인슐린 주사의 유효성(有效性)을 나타내지 않는 경우가 많다.As such, diabetic causes serious complications, so the main purpose of diabetes treatment is to manage thorough blood glucose control. Although insulin injection has an absolute effect on blood glucose control of patients with type I diabetes because insulin secretion is the cause, the insulin sensitivity of patients with type II diabetes is lowered, so the effectiveness of insulin injections ) In many cases.
이와 같은 제Ⅱ형 당뇨병 환자에 대한 치료로는 식이제한을 하여 식사성의 과잉 칼로리 섭취를 제한하는 요법과 체내의 칼로리 소비를 촉진시키기 위한 운동요법을 들 수 있는데, 식이제한은 장기간 지속되게 되면 오히려 건강에 악영향을 미칠 수가 있다.Treatment of these type II diabetes patients includes dietary restrictions to limit excessive dietary calorie intake and exercise to promote calorie consumption in the body. Dietary restrictions, if continued for a long period of time, Can be adversely affected.
따라서, 식이제한 및 운동요법으로 눈에 띄는 진전이 없는 환자에 대해서는 당뇨병약의 사용(설포닐우레아제, 비구아나이드제 등)이 시도되는데, 이들 약제는 큰 문제점을 안고 있다. 이를테면 설포닐우레아제(SU제)는 1970년대부터 제2세대의 약제가 사용되고 있는 오랜 사용경험을 갖는 약제이지만, 혈당치가 너무 내려가 저혈당을 일으키는 것으로 알려져 있다. 또 공복감을 증강시키기 때문에 식이제한으로부터 일탈되기 쉬워 혈당 콘트롤을 실패하게 함과 동시에 비만을 조장하는 경우도 많다. 이와 같은 문제가 있기 때문에 설포닐우레아제의 사용 시에는 의사에 의한 엄격한 콘트롤이 필수적이다.Therefore, the use of diabetes medicines (sulfonylureas, acetaminides, etc.) is attempted in patients who do not have noticeable progress with dietary restriction and exercise therapy, and these drugs have great problems. For example, sulfonylureas (SU agents) have been used for a long time since the 1970s, but the blood sugar level is too low to cause hypoglycemia. In addition, because it increases the hunger feeling, it is easy to deviate from the dietary restriction, and the control of the blood sugar is made to fail, and also the obesity is promoted in many cases. Because of these problems, strict control by physicians is essential when using sulfonylureas.
한편, 비구아나이드제(BG제)도 1970년대부터 사용되어 오고 있는 약제이지만, 이 약제는 사용 개시 후 얼마되지 않아 부작용으로서 락틱산 애시도시드(Lactic acid acidosis)의 발생이 다수 보고되었다. 최근 들어 그 사용방법과 유효성이 재검토되고 있지만, 비구아나이드제 역시 의사의 엄격한 관리하에서의 사용이 필수적이다.On the other hand, although an acetylating agent (BG agent) has also been used since the 1970s, there have been many reports of the occurrence of lactic acid acidosis as a side effect of this agent shortly after use. Recently, its use and effectiveness have been reviewed, but the use of acetaminophen in the strict management of the physician is also essential.
이와 같은 상황에서 새로운 경구(經口) 당뇨병약의 개발이 시도되고, 또 α-글루코시다아제(α-glucosidase) 저해제나 인슐린 작용 증강제 등이 개발되어 왔으나, 그 효과가 아직 미검증된 상태이다. 현재 인슐린 작용 증강제인 트로글리타존(troglitazone)은 간장해(肝障害)의 부작용에 의해 개발이 중지된 상태이다.In this situation, the development of a new oral (经 口) diabetes drug has been attempted, and α-glucosidase inhibitors and insulin action enhancers have been developed, but the effect has not yet been verified. Currently, insulin action enhancer troglitazone (troglitazone) has been stopped due to the side effects of liver damage (liver damage).
이와 같이 당뇨병에 대해서는 환자가 안심하고 사용할 수 있는 안전성이 높은 경구약제는 거의 전무한 상황이고, 실제 치료 효과를 기대할 수 있는 방법은 식이제한이라고 해도 과언이 아니지만, 앞에서 언급한 바와 같이 식이제한을 장기간 이어나갈 경우, 오히려 건강에 악영향을 미칠 수가 있다.As described above, there is almost no safe oral medicine that can be safely used for patients with diabetes. It is not an exaggeration to say that the method which can expect the actual treatment effect is the dietary restriction. However, as mentioned above, If you go out, it can adversely affect your health.
이러한 식이제한의 단점을 극복하기 위해 당뇨병용 저칼로리 식품이 많이 개발되고 있으나, 당뇨병의 치료에 대한 공헌은 극히 부분적인 것에 지나지 않는다. 또한, 당뇨병에 특징적으로 발생하는 합병증에 대한 치료제도 현재는 없기 때문에 혈당치를 관리함으로써 합병증의 예방을 겸하고 있는 것이 현 실정이다.To overcome the shortcomings of this dietary restriction, many low-calorie foods for diabetes have been developed, but the contribution to the treatment of diabetes is only marginal. In addition, there is currently no treatment for the complications that are characteristic of diabetes. Therefore, it is currently being used to prevent complications by managing blood glucose levels.
따라서, 당뇨병에 대해서는 인체에 안전성이 높은 유용한 약제 또는 식이제한 중에도 안심하고 섭취할 수 있는 유효한 기능성 식품 등의 개발이 요구되어진다.Therefore, for diabetes, it is required to develop a useful drug which is highly safe for human body, or an effective functional food which can be safely consumed even during dietary restriction.
따라서, 본 발명자들은 인체에 안정성이 높으면서 당뇨질환을 개선 및 예방할 수 있는 식품을 예의 연구한 결과, 본 발명의 방법으로 제조된 식품이 항당뇨의 작용 기전을 활성화시키고 나아가 천연성분들로만 이루어져 인체에도 부작용이 없음을 확인함으로써 본 발명을 완성하기에 이르렀다.Accordingly, the present inventors have intensively studied foods that can improve or prevent diabetes mellitus with high stability to the human body. As a result, the inventors of the present invention found that the food prepared by the method of the present invention activates the action mechanism of anti-diabetic, The present inventors have completed the present invention.
본 발명의 과제 해결 수단 구성은, a) 여주 54.5 - 71.5중량%, 산약 8.0 - 11.5중량%, 상엽 4.5 - 7.4중량%, 양파 1.5 - 2.5중량%, 밀크씨슬 3.5 - 5.8중량%, 현미 1.5 - 2.5중량%, 서목태 1.5 - 2.5중량%, 솔잎 1.5 - 2.5중량%, 당귀 1.5 - 2.5중량%, 흑임자 1.5 - 2.5중량%, 건강 1.5 - 2.5중량%를 혼합하여 혼합물을 마련하는 단계; b) 상엽 50 - 54중량% 및 오가피 46 - 50중량%에 물을 첨가하고, 70 - 80℃의 온도에서 2 - 3시간 열수추출 과정을 거친 후 추출액을 수득하는 단계; c) 상기 b) 단계의 추출액을 여과하여 여액을 수득하는 단계; d) 상기 c) 단계의 여액을 농도가 23brix 이상 이를때까지 농축하여 농축액을 수득하는 단계; e) 상기 a) 단계의 혼합물과 d) 단계의 농축액을 1:0.4-0.6의 비율로 혼합하는 단계로 이루어지는 것을 특징으로 한다.The composition of the present invention comprises a) 54.5 to 71.5% by weight of flax, 8.0 to 11.5% by weight of acid, 4.5 to 7.4% by weight of onion, 1.5 to 2.5% by weight of onion, 3.5 to 5.8% Preparing 1.5 to 2.5% by weight of pine needle, 1.5 to 2.5% by weight of pine needle, 1.5 to 2.5% by weight of Angelica keiskei, 1.5 to 2.5% by weight of blackberry and 1.5 to 2.5% by weight of health; b) adding water to 50 to 54% by weight of the upper leaves and 46 to 50% by weight of the oak, extracting the extract after 2 to 3 hours of hot water extraction at a temperature of 70 to 80 ° C; c) filtering the extract of step b) to obtain a filtrate; d) concentrating the filtrate of step c) until the concentration reaches 23 brix or more to obtain a concentrate; e) mixing the mixture of step a) and the concentrate of step d) in a ratio of 1: 0.4-0.6.
또한, 상기 c) 단계의 여액은 b) 단계의 추출액을 원심분리하여 상등액을 수득한 다음, 상기 상등액을 여과하여 수득된 것임을 특징으로 한다.The filtrate of step c) is obtained by centrifuging the extract of step b) to obtain a supernatant, and then filtering the supernatant.
또, 상기 a) 단계의 현미는 현미배아 또는 호분층 중 어느 하나 또는 2가지 모두가 혼합된 것임을 특징으로 한다.In addition, the brown rice in the step (a) is characterized in that any one or both of the brown rice embryo or the colony layer is mixed.
또한, 상기 e) 단계를 거친 혼합물은 분말제, 환제, 정제, 캅셀제, 액제 및 현탁제 형태 중 어느 하나의 제형으로 제형화 되는 것을 특징으로 한다.In addition, the mixture obtained through step e) is characterized in that it is formulated into a powder, a pill, a tablet, a capsule, a liquid and a suspension.
상기와 같은 구성을 갖는 본 발명의 방법으로 제조된 당뇨 예방 및 개선용 식품은 인슐린(insulin) 저항성을 완화시켜 혈장 내 인슐린 농도를 감소시키면서 혈당을 강하(降下)시킬 수 있고, 인슐린 저항성 또는 인슐린 감수성(感受性)을 개선함으로써 당뇨의 예방 및 개선에 효과가 있으며, 유효성(有效性)을 발휘하는 성분들이 천연물질로 이루어져 인체에 대한 부작용이 없고, 다양한 제형으로 형성하여 범용성(凡用性)을 확장시킴으로써 산업상 이용 가능성이 높은 효과가 있다.The diabetes preventive and remedy food prepared by the method of the present invention having the above-described structure can lower the insulin resistance in the plasma by lowering the insulin resistance, and can lower the blood sugar while reducing insulin resistance or insulin sensitivity (Susceptibility), thereby preventing and improving diabetes, and the ingredients showing efficacy are made of natural substances, so that they do not have side effects on the human body, and they are formed into various formulations to expand the versatility So that it is highly likely to be used industrially.
도 1은 본 발명의 바람직한 일 실시예에 따른 당뇨 예방 및 개선용 식품의 제조방법을 나타낸 공정도.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a process diagram showing a method of manufacturing a food for preventing and improving diabetes according to a preferred embodiment of the present invention; FIG.
본 발명의 당뇨 예방 및 개선용 식품의 제조방법은 도 1에 나타낸 바와 같이,As shown in Fig. 1, the method of the present invention for producing diabetes preventive /
a) 여주 54.5 - 71.5중량%, 산약 8.0 - 11.5중량%, 상엽 4.5 - 7.4중량%, 양파 1.5 - 2.5중량%, 밀크씨슬 3.5 - 5.8중량%, 현미 1.5 - 2.5중량%, 서목태 1.5 - 2.5중량%, 솔잎 1.5 - 2.5중량%, 당귀 1.5 - 2.5중량%, 흑임자 1.5 - 2.5중량%, 건강 1.5 - 2.5중량%를 혼합하여 혼합물을 마련하는 단계;a) Leeks 54.5 - 71.5% by weight, Acacia 8.0 - 11.5% by weight, Upper leaf 4.5 - 7.4% by weight, Onion 1.5 - 2.5% by weight, Milk Seeds 3.5 - 5.8% by weight, Brown rice 1.5 - 2.5% Preparing 1.5 to 2.5 wt% of pine needle, 1.5 to 2.5 wt% of Angelica keiskei, 1.5 to 2.5 wt% of blackberry, and 1.5 to 2.5 wt% of health to prepare a mixture;
b) 상엽 50 - 54중량% 및 오가피 46 - 50중량%에 물을 첨가하고, 70 - 80℃의 온도에서 2 - 3시간 열수추출 과정을 거친 후 추출액을 수득하는 단계;b) adding water to 50 to 54% by weight of the upper leaves and 46 to 50% by weight of the oak, extracting the extract after 2 to 3 hours of hot water extraction at a temperature of 70 to 80 ° C;
c) 상기 b) 단계의 추출액을 여과하여 여액을 수득하는 단계;c) filtering the extract of step b) to obtain a filtrate;
d) 상기 c) 단계의 여액을 농도가 23brix 이상 이를때까지 농축하여 농축액을 수득하는 단계;d) concentrating the filtrate of step c) until the concentration reaches 23 brix or more to obtain a concentrate;
e) 상기 a) 단계의 혼합물과 d) 단계의 농축액을 1:0.4-0.6의 비율로 혼합하는 단계로 이루어진다.e) mixing the mixture of step a) and the concentrate of step d) in a ratio of 1: 0.4-0.6.
이하, 상기와 같은 방법으로 제조되는 식품에 사용되는 각각의 원료들에 대하여 설명하면 다음과 같다.Hereinafter, each raw material used in the food produced by the above-described method will be described.
- 다 음 -- next -
1) 여주1) Yeoju
여주(margose)는 식물성 인슐린(insulin)과 카라틴 성분이 함유되어 있어 인슐린 분비와 혈당의 분해를 도와 혈당강하(血糖降下) 작용이 뛰어나다. 또한, 비타민 C가 매우 풍부하여 피로회복 및 눈 건강은 물론, 피부보습, 피부노화방지, 피부트러블 개선, 피부진정 효과까지 있다. 이외에도 붓기나 통증을 일으키는 전염병과 피부가 붓거나 곪아 터져 잘 낫지 않는 증상을 완화시키는 효능도 지니고 있다.Margose contains plant insulin and carraenine, which helps insulin secretion and breakdown of blood sugar, and is excellent in blood sugar (hypoglycemic) action. In addition, vitamin C is very abundant, fatigue and eye health, as well as skin moisturizing, skin aging prevention, skin trouble improvement, skin soothing effect. In addition, it has the efficacy of relieving the symptoms of swelling and pain, epidemics and swelling and tingling of the skin.
2) 산약2)
산약(山藥)은 식욕이 감퇴하며 원기가 부족할 때, 백출(白朮)ㆍ연밥ㆍ인삼 등과 함께 달여 복용하며, 정액이 새거나 수면 시 땀을 흘릴 경우, 숙지황ㆍ산수유 등과 달여 복용한다. 또한, 산약은 비기능(脾機能)을 높여 권태감, 무력감, 음식감소, 설사 등을 다스리며 폐음을 보해 해수, 천식, 가래를 없애고, 소갈증, 허리와 무릎이 시린 증상, 유정, 조루증, 소변을 자주 보는 증상, 신체허약과 빈혈, 사지마비동통 등에 사용한다. 주 효능으로는 장관활동자극, 혈당강하, 항노화작용 등이 보고되었다.Sanmek (山药) when the appetite is weak and refreshing, it is taken in conjunction with Baekjung, Yongbap, Ginseng, etc., and if you have semen leaking or sweating when you sleep, it will be taken with Sukjihuang, In addition, it enhances non-functioning (splenic function) to control seizures, asthma, and sputum by controlling lethargy, helplessness, food reduction, diarrhea and so on. Symptoms, physical weakness, anemia, and limb paralysis. The main effects were stimulation of intestinal activity, hypoglycemia, and anti-aging effects.
3) 상엽3)
상엽(桑葉)은 뽕나무와 산뽕나무의 잎을 말린 것으로 상상엽(霜桑葉)이라고도 불린다. 맛은 쓰고 달며 성질은 서늘하며 폐경(肺經)ㆍ간경(肝經)에 작용한다. 또한, 풍열사(風熱邪)를 없애고 혈열(血熱)을 제거하며 출혈을 멎게 하고 눈병을 낫게 한다. 주 효능으로는 혈당 강하 작용ㆍ혈압 강하 작용ㆍ이뇨 작용ㆍ항균 작용이 밝혀졌다.Mulberry leaves are dried with leaves of mulberry trees and mountain mulberry trees, also called frost 桑葉. Taste is appetite, temperate and cool, and acts on menopause (肺 经) and liver (肝 经). It also eliminates wind chill, eliminates hemorrhagic fever, stops bleeding, and heals eye diseases. The main effects were hypoglycemic action, hypotensive action, diuretic action and antibacterial action.
4) 양파4) Onions
양파는 주로 6 - 7월에 잎이 쓰러지고 약간의 녹색을 지닐 때 수확하는데, 비늘줄기가 크기 전에 뽑아서 잎을 식용하는 것도 있다. 양파는 주로 비늘줄기를 식용으로 사용하는데, 비늘줄기에서 나는 독특한 냄새는 아황산프로필ㆍ황화알릴 등의 화합물 때문이다. 이것은 생리적으로 소화액 분비를 촉진시키고 흥분ㆍ발한ㆍ이뇨 등의 효과가 있다.Onions are harvested mainly in June-July when the leaves fall and have a slight green color. Some scales are picked before the leaves are edited. The onion is mainly used for edible use of scaly stem. The unique smell from the stem of the scales is due to compounds such as propyl sulfite and allyl sulfide. It physiologically promotes the secretion of digestive juices and has effects such as excitement, sweating, and diuretic.
5) 밀크씨슬5) Milk seeds
밀크씨슬(milk thistle)은 속에 들어있는 실리마린(silymarin)의 성분이 유효작용을 하는데, 실리마린은 세포막을 유리기로부터 보호하는 작용을 함으로써, 세포를 튼튼하게 유지하게 하고, 특히 간세포에 대한 친화력이 강하다. 간에 대한 실리마린의 산화방지 역할은 비타민 E의 약 10배에 달하고, 강력한 산화방지제인 슈퍼 옥사이드 디스뮤테이즈(superoxide dismutase) 및 글루타타이언(glutathaione)의 농도를 높여줌으로서 간에 대한 산화방지 역할 뿐 아니라 일반적인 산화방지제 역할도 한다. 또한, 혈당을 조절해주는 작용을 하여 당뇨병에도 좋은 효능을 나타낸다.Milk seeds (milk thistle) is a component of the silymarin (silymarin) is effective for the action of silymarin protects the cell membrane from the free radicals to keep the cells strong, especially strong affinity for hepatocytes . The antioxidant role of silymarin in the liver is about 10 times that of vitamin E, and by increasing the concentration of superoxide dismutase and glutathione, which are strong antioxidants, It also acts as an antioxidant. In addition, it acts to regulate blood sugar and shows good efficacy against diabetes.
6) 현미6) Brown rice
현미(玄米)는 그 구조가 과피(果皮), 종피(種皮), 호분층(湖粉層) 등의 겨층이라고 불리는 쌀알의 기부(基部)에 소부분을 차지하는 배아(胚芽)와, 나머지 대부분의 배유로 형성되어 있다. 각 부분의 현미전립에 대한 중량비는 겨층 5 - 6%, 배아 2 - 3%, 배유 92%이다. 현미의 주 효능으로는 현미는 섬유질이 풍부하여 변비에 좋고, 체내의 중금속을 배출시켜 주며 현미배아의 피틴산(phytic acid)이라는 해독 물질이 농약, 세제 등을 해독한다. 또한, 피부를 건강하게 만들어 주는 등 현미는 몸과 신체를 맑게 해준다.Brown rice is an embryo whose structure occupies a small part of the base of the rice grain called pebbles such as pericarp, seed coat and lacustrine layer, Respectively. The weight ratio of each part to the brown rice is 5 - 6% for the bottom layer, 2 - 3% for the embryo and 92% for the endosperm. The main effect of brown rice is that brown rice is rich in fiber, which is good for constipation, it releases heavy metals in the body, and detoxification substance called phytic acid in brown rice embryo decodes pesticides and detergents. In addition, it makes your skin healthy, and brown rice cleanses your body and body.
7) 서목태7) Seomok-tae
서목태(鼠目太)는 검은콩의 일종으로 껍질은 까맣고 크기는 보통 검은콩보다 훨씬 작아 마치 쥐눈처럼 생겼다고 하여 서목태, 일명 쥐눈이콩이라고도 불린다. 특히, 약성(藥性)이 뛰어나 예로부터 식용보다는 약용으로 쓰였다. 서목태는 고혈압, 동맥경화, 심장질환 등 각종 성인병의 예방과 치료에 좋은 식품으로 인정받고 있다. 특히, 당뇨 환자가 아침, 저녁 공복에 설사 증세가 없을 정도로 복용하면 당뇨 치료에 상당한 도움이 된다. 또한, 해독력이 뛰어나 체내에 들어가 파괴된 인체조직을 빠른 속도로 회복시켜주고 갖가지 독성을 풀어주는 역할을 한다.Seomok-tae is a type of black bean, whose skin is black and its size is much smaller than that of black beans. In particular, it is excellent in medicine and has been used for medicines since ancient times rather than edible. Seomyeongtae is recognized as a good food for prevention and treatment of various diseases such as hypertension, arteriosclerosis and heart disease. Diabetes patients, especially in the morning and evening fasting, diarrhea without symptoms of diarrhea is very helpful for the treatment of diabetes. In addition, it has excellent detoxification ability to recover the destroyed human tissue at a rapid rate and to release various toxicities.
8) 솔잎8) Pine needles
솔잎은 동의보감에 따르면, '솔잎을 오랫동안 생식하면 늙지 않고, 원기가 왕성해지며, 머리가 검어지고, 추위와 배고픔을 모른다'고 했다. 솔잎은 비타민 A를 많이 함유하고 있어 혈액을 깨끗하게 해주고 고혈압을 예방하는 효과가 있는 것으로 알려졌다. 또한, 간장질환, 위장질환, 신경계질환, 순환계질환과 피부보호 및 중풍, 동맥경화증, 고혈압, 당뇨병 같은 노인성 질환을 예방하는 효과도 있다.According to Dongbokbo, pine needles do not age when grown for a long time, become refreshing, their hair become black, and they do not know cold and hunger. Pine needles contain a lot of vitamin A, which cleanse blood and prevent hypertension. It also has the effect of preventing geriatric diseases such as liver diseases, gastrointestinal diseases, neurological diseases, circulatory diseases and skin protection and stroke, arteriosclerosis, hypertension and diabetes.
9) 당귀9) Angelicae
당귀(當歸)는 마땅히 돌아오기를 바란다는 뜻을 담아 '담귀'라는 이름을 붙였다고 전해진다. 이는 오래 전 중국에서 부인들이 싸움터에 나가는 남편을 염려하며 품속에 당귀를 넣어줬다는 풍습에서 유래하는데, 전쟁터에서 기력을 다했을 때 당귀를 먹으면 다시 기운이 회복되어 돌아올 수 있다고 믿었기 때문이다. 주 효능은 피가 부족할 때 피를 생성해 주는 보혈(補血)작용이 주를 이룬다. 중국당귀나 왜당귀의 뿌리로 만든 당귀는 보혈작용이 뛰어나다. 하지만 참당귀의 뿌리로 만든 당귀는 보혈작용 보다는 피를 원활히 순환하게 해주는 활혈(活血)작용이 더 뛰어나며, 항암효과 및 혈압강하 작용이 강하다.It is said that the gangwi (當 帰) is named 'Duckwoo' with the intention of wanting to return. This is because of the tradition of long ago in China, when the wife was worried about her husband going to the battlefield and put Angelica in her bracelet, she believed that when she was full of energy on the battlefield, she could recover her energy again after eating Angelica. The main efficacy is predominantly the blood-producing (blood-producing) action of producing blood when blood is scarce. Chinese Angelica, why Angelica, made from the root of Angelica gigas, is excellent in blood circulation. However, Angelica root, made from the root of Angelica gigas, has better antithrombotic effect and blood pressure lowering effect, which makes the blood circulate more smoothly than the blood.
10) 흑임자10) The black soldier
흑임자(黑荏子)는 예로부터 중국에서는 깨 중에서도 검정깨인 흑임자를 불로장수의 식품이라 하여 귀중하게 여겨왔고 선약(仙藥)이라 취급되어 왔다. 우리나라에서도 역시 건강이나 장수를 위한 식품으로 애용되었다. 흑임자는 항산화작용을 하는 토코페놀(tocoferol)과 정력에 좋은 필수아미노산이며 세포구성체인 DNA의 활성작용과 치매의 예방 및 치료효과에 탁월한 효능을 지니고 있는 세라늄(selenium), 세사몰(sesamol), 세사미놀(sesaminol) 등의 성분이 함유되어 있다. 또한, 항암효능도 있는 것으로 알려져 있는데, 동물실험 보고서에 의하면 피부암 억제능력이 약 60%, 위장암 억제능력이 약 85%, 폐암 억제능력이 약 75%라고 한다.Black saucer has been regarded as a longevity food and has been regarded as a medicine since it has been a black sesame among black beans in China since ancient times. In Korea, it was also used as food for health and longevity. Selenium (sesamol), which is an excellent antioxidant tocopherol (tcoferol), is an essential amino acid for vigor, and has an excellent effect on the activity of DNA constituting the cell and the preventive and therapeutic effect of dementia. Sesaminol and other ingredients. It is also known that it has anticancer efficacy. According to the animal test report, it is said that the skin cancer suppressing ability is about 60%, the gastric cancer suppressing ability is about 85%, and the lung cancer suppressing ability is about 75%.
11) 건강11) Health
건강(또는 '생강'이라고도 함)은 동인도의 힌두스댄 지역이 원산지로 추정되며 중국에서는 약 2,500여년 전에 재배되었다는 기록이 있다. 지금의 사천성이 건강의 원산지로 알려져 있다. 우리나라에서는 고려사(현종 9년, 1018년)에 건강 재배에 관한 내용이 최초로 기록되었으며 왕의 하사품으로 건강이 쓰여졌다고 기록되어 있다. 주 효능으로는 위액분비촉진, 장관 연동작용 활성화, 소화촉진, 구토를 가라앉히며 심장을 흥분시켜 혈압을 상승하게 하고 혈액순환을 촉진한다. 또한, 항염, 진통작용, 억균작용도 한다.Health (also known as "ginger") is a Hindu-Dan area in the East India, which is believed to be the country of origin and was cultivated about 2,500 years ago in China. Now Sichuan province is known as the origin of health. In Korea, the contents of health cultivation were recorded for the first time in Goryeo (9th year of King Hyeongjong, 1018) and it is recorded that the health was written by the royal family. Main effects include stimulation of gastric juice secretion, activation of intestinal peristalsis, promotion of digestion, vomiting, sedation, stimulation of the heart, blood pressure and blood circulation. It also has anti-inflammatory, analgesic and acaricidal action.
12) 오가피12) Ogaki
오가피(五加皮)는 잎이 다섯 개로 갈라져 있는데, 하나의 가지에 다섯 개의 잎이 나는 것이 좋다 하여 오가(五佳)라고 칭하였다가 지금은 오가(五加)로 기재하게 되었다. 주 효능으로는 면역증강, 항산화, 항피로, 항고온, 항자극작용, 내분비기능조절, 혈압조절, 항방사능, 해독작용을 들 수 있다.Ogaki (五加皮) is divided into five leaves, it is good to have five leaves on one branch, called Oga, and now it is described as Oga (五 加). Main effects include immune enhancement, antioxidant, anti-fatigue, anti-hypertension, anti-irritation, endocrine control, blood pressure control, anti-radioactivity and detoxification.
이하, 상기와 같은 효능을 갖는 원료를 이용한 당뇨 예방 및 개선용 식품의 제조방법을 각 단계별로 구분하여 설명하면 다음과 같다.Hereinafter, a method for preparing a food for preventing or improving diabetes using raw materials having the above-described effects will be described separately for each step.
- 다 음 -- next -
a) 단계a) Step
상기 a) 단계는, 여주 54.5 - 71.5중량%, 산약 8.0 - 11.5중량%, 상엽 4.5 - 7.4중량%, 양파 3.5 - 5.8중량%, 밀크씨슬 3.5 - 5.8중량%, 현미 1.5 - 2.5중량%, 서목태 1.5 - 2.5중량%, 솔잎 1.5 - 2.5중량%, 당귀 1.5 - 2.5중량%, 흑임자 1.5 - 2.5중량%, 건강 1.5 - 2.5중량%를 혼합하여 혼합물을 마련하는 단계로써,Wherein the step a) comprises the steps of: 54.5 to 71.5% by weight of mallow, 8.0 to 11.5% by weight of acid, 4.5 to 7.4% by weight of onion, 3.5 to 5.8% by weight of onion, 3.5 to 5.8% Preparing 1.5 to 2.5% by weight of pine needle, 1.5 to 2.5% by weight of pine needle, 1.5 to 2.5% by weight of Angelica keiskei, 1.5 to 2.5% by weight of blackberry and 1.5 to 2.5%
상기 열거한 원료들은 전처리 단계를 거칠 수 있는데, 이를테면 각 원료들을 깨끗한 물에 씻은 후 적절한 크기로 분쇄하여 준비할 수 있다. 이때, 표면에 묻은 이물질을 제거하고, 또한 씨앗을 포함하는 열매의 경우, 내부에 들어있는 씨앗 등을 제거할 수 있다.The raw materials listed above can be subjected to a pretreatment step, such as washing each raw material in clean water and then pulverizing to an appropriate size. At this time, it is possible to remove the foreign substances on the surface, and in the case of the fruit including the seed, the seeds contained therein can be removed.
여기서, 상기 원료들은 유효(有效)성분의 효능이 잘 발휘되도록 곱게 분쇄한 것을 사용하는 것이 바람직하나, 특별히 분말 입자의 크기는 한정하지 않는다.Here, the raw materials are preferably finely pulverized so as to exhibit an effective effect of the effective component, but the size of the powder particles is not particularly limited.
한편, 상기 여주는 7월경에 수확한 10 - 20cm 길이의 미성숙된 여주를 사용하는게 좋다. 이는 상기 미성숙된 여주에 식물인슐린(p-insulin)과 카란틴(charantin), 비타민 C 등의 유효성분이 다량 함유되어 있기 때문이다. 여기서, 상기 여주는 총 중량에 대하여 54.5중량% 미만으로 함유되면 식물성 인슐린과 카란틴 성분의 활성 작용이 미비해지고, 71.5중량%를 초과하여 함유되면 쓴맛이 강해질 수 있다.On the other hand, it is recommended that the Yeoju be matured about 10 - 20cm long harvested in July. This is due to the fact that the immature rumen contains a large amount of active ingredients such as plant insulin (p-insulin), carantine, vitamin C and the like. If the yeast is contained in an amount less than 54.5% by weight based on the total weight, the activity of the plant insulin and carotene ingredient is insufficient. If the yeast content exceeds 71.5% by weight, the bitter taste may become strong.
상기 산약은 혈당강하(血糖降下) 작용이 탁월한 원료로써, 총 중량에 대하여 8중량% 미만으로 함유되면 전술한 혈당강하 작용이 미비해지고, 11.5중량%를 초과하여 함유되면 섭취 시 위장에 부담을 줄 수 있다.If the amount is less than 8% by weight based on the total weight, the blood glucose lowering action is insufficient. When the amount is more than 11.5% by weight, .
상기 상엽 역시 산약과 마찬가지로 혈당강하 작용에 더하여 혈압강하 작용 및 이뇨 작용 등이 탁월한 원료로써, 총 중량에 대하여 4.5중량% 미만으로 함유되면 전술한 효능, 즉 혈당강하, 혈압강하 및 이뇨 작용 등에서 효능을 발휘하지 못하고, 7.4중량%를 초과하여 함유되면 쓴맛과 단맛이 매우 강해질 수 있다.If the content of the topical leaf is less than 4.5% by weight based on the total weight of the raw material, the blood pressure lowering action and the diuretic action as well as the blood glucose lowering action, If it is contained in an amount exceeding 7.4% by weight, the bitter taste and sweet taste may become very strong.
상기 양파는 6 - 7월에 잎이 쓰러지고 약간의 녹색을 지닐 때 수확하는게 가장 좋은데, 이는 아황산프로필 및 황화알릴 등의 화합물의 활성이 가장 활발해지기 때문이다. 한편, 상기 양파는 총 중량에 대하여 3.5중량% 미만으로 함유되면 양파의 효능, 다시 말해서 소화액 분비의 촉진이 더져짐으로 인해, 인체에 유효성분의 침투가 곤란해질 수 있으며, 5.8중량%를 초과하여 함유되면 아황산프로필 및 황화알릴 성분이 과해져 양파 특유의 냄새가 진해질 수 있다.The onion is best harvested from June to July when the leaves collapse and have a slight green color, because the activity of the compounds such as sulfite propylate and allyl sulfide becomes most active. On the other hand, when the onion is contained in an amount of less than 3.5% by weight based on the total weight, penetration of the active ingredient into the human body may become difficult due to the effect of the onion, that is, the promotion of digestive juice secretion, If it is contained, the profile of sulfurous acid and the allyl sulfide component are over-mixed, and the odor peculiar to the onion may be intensified.
상기 밀크씨슬은 실리마린(silymarin)의 성분이 유효작용을 하는데, 이 실리마린의 성분은 세포를 튼튼하게 유지하게 할 뿐 아니라, 특히 간세포에 대한 친화력이 강하다. 또한, 혈당 조절 기능이 탁월하여 당뇨병에 좋은 효능을 나타낸다. 한편, 상기 밀크씨슬은 총 중량에 대하여 3.5중량% 미만으로 함유되면 실리마린의 성분이 미비해져 전술한 효능을 발휘하기가 어렵고, 5.8중량%를 초과하여 함유되면 실리마린의 성분이 과해져 오히려 인체의 간에 악영향을 미칠 가능성이 높아진다.The milk seeds have a beneficial effect on the components of silymarin. The components of the silymarin not only keep the cells strong but also have a strong affinity for hepatocytes. In addition, it has excellent blood glucose control function and shows good efficacy on diabetes. On the other hand, if the milkcass is contained in an amount less than 3.5% by weight based on the total weight of the composition, the component of the silymarin is insufficient and it is difficult to exhibit the above effect. If the milkcumin is contained in an amount exceeding 5.8% by weight, There is a high possibility of having an adverse effect on each other.
상기 현미는 그 구조에 따라 다양한 명칭이 사용되는데, 본 발명에서는 현미배아 또는 호분층 중 어느 하나 또는 2가지 모두가 혼합된 것을 사용할 수 있다. 또 상기 현미는 체내의 중금속을 배출시켜 주며 피틴산(phytic acid)이라는 해독물질이 몸과 신체를 맑게 해준다. 또한, 상기 현미배아와 호분층에는 리놀레산(linolenic acid)이 풍부하게 함유되어 있어 동맥경화나 노화방지에도 좋다. 한편, 상기 현미가 총 중량에 대하여 1.5중량% 미만으로 함유되면 전술한 효능을 발휘하기가 어렵고, 2.5중량%를 초과하여 함유되면 전술한 효능은 충분히 발휘될 수 있으나, 비용을 고려할 경우, 경제적이지 못하다.The brown rice may have various names according to its structure. In the present invention, any one or both of a brown rice embryo or a colony can be used. The brown rice also releases heavy metals in the body, and phytic acid, a detoxifying substance, cleanses the body and body. In addition, the brown rice embryo and the colonic layer are rich in linolenic acid, which is good for arteriosclerosis and anti-aging. On the other hand, when the brown rice is contained in an amount less than 1.5% by weight based on the total weight, it is difficult to exhibit the above-mentioned effect. When the brown rice is contained in an amount of more than 2.5% by weight, the above-mentioned effect can be sufficiently exhibited. Can not do it.
상기 서목태는 검은콩의 일종으로 고혈압, 동맥경화, 심장질환 등 성인병의 예방과 치료에 좋은 식품으로 인정받고 있으며, 특히 당뇨환자에게 탁월한 효능을 나타낸다. 한편, 상기 서목태는 총 중량에 대하여 1.5중량% 미만으로 함유되면 성인병의 예방 및 치료 또는 당뇨병에 대해 항작용의 기전이 낮아지고, 2.5중량%를 초과하여 함유되면 비용을 고려할 경우, 경제적이지 못하다.This is a kind of black bean, which is recognized as a good food for prevention and treatment of adult diseases such as hypertension, arteriosclerosis and heart disease, and shows excellent efficacy especially for diabetic patients. On the other hand, if it is contained in an amount of less than 1.5% by weight based on the total weight, the mechanism of anti-action against the prevention or treatment of adult diseases or diabetes is lowered, and if it is contained in an amount exceeding 2.5% by weight, the cost is not economical.
상기 솔잎은 비타민 A가 풍부하여 혈액을 깨끗하게 해주고 고혈압을 예방하는 효과가 있다. 특히, 당뇨병, 고혈압 등 노인성 질환을 예방하는 효과가 탁월하다. 한편, 상기 솔잎은 총 중량에 대하여 1.5중량% 미만으로 함유되면 전술한 효과, 즉 당뇨병, 고혈압 같은 노인성 질환을 예방할 수 있는 기전작용이 미비해지고, 2.5중량%를 초과하여 함유되면 저혈압을 유발할 수 있는 가능성이 생길 수도 있다.The pine leaves are rich in vitamin A, which cleans blood and prevents hypertension. In particular, the effect of preventing diseases such as diabetes and hypertension is excellent. On the other hand, when the pine needle is contained in an amount of less than 1.5% by weight based on the total weight of the pine needle, the above-mentioned effect, that is, the mechanism of action to prevent geriatric diseases such as diabetes and hypertension is insufficient. Possibilities may arise.
상기 당귀는 피를 생성해 주는 보혈(補血)작용과 피를 원활히 순환하게 해주는 활혈(活血)작용이 뛰어나며, 또한 항암효과 및 혈압강하 작용이 강한 약재로써, 총 중량에 대하여 1.5중량% 미만으로 함유되면 전술한 효능, 다시 말해 보혈작용, 활혈작용, 항암효과 및 혈압강하 작용이 미비해지고, 2.5중량%를 초과하여 함유되면 섭취 시 인체에 열이 과도하게 발생할 수도 있다.The Angelica gigas have excellent anticancer effect and blood pressure lowering effect, which are excellent in blood circulation (blood supply) for producing blood and blood circulation (blood) for circulating blood smoothly. It is less than 1.5% by weight based on the total weight In other words, the above-mentioned efficacy, that is, the blood circulation effect, the hysteresis effect, the anticancer effect and the blood pressure lowering effect are insufficient, and when it exceeds 2.5 wt%, the human body may overheat.
상기 흑임자는 예로부터 불로장수의 식품이라 하여 귀중하게 여겨온 식품으로, 항산화작용을 하는 토코페놀(tocoferol)이 풍부하고 세포구성체인 DNA의 활성작용을 우수하게 해주는 효능이 있다. 한편, 상기 흑임자는 1.5중량% 미만으로 함유되면 항산화작용 및 DNA의 활성작용이 미비해지고, 2.5중량%를 초과하여 함유되면 비용을 고려할 경우, 경제적이지 못하다.The black potato is a food that has been regarded as a longevity food since ancient times. It is rich in tocopherol which is antioxidative, and has an effect of excelling the activity of DNA which is a cell constituent. On the other hand, when the black sugar is contained in an amount of less than 1.5% by weight, the antioxidative activity and the activity of DNA activity are insufficient. If the black star is contained in an amount of more than 2.5% by weight, the cost is not economical.
상기 건강은 '생강'의 다른 명칭으로 주 효능으로 심장을 흥분시켜 혈압을 상승하게 하고 혈액순환을 촉진한다. 한편, 상기 건강은 1.5중량% 미만으로 함유되면 혈액순환이 저하되고, 2.5중량%를 초과하여 함유되면 과도한 혈액순환 작용으로 혈압이 기준치 이상으로 급격하게 상승할 수도 있다.The health is another name of 'ginger', which excites the heart with its main effect, which increases blood pressure and promotes blood circulation. On the other hand, when the health is less than 1.5% by weight, the blood circulation is decreased. When the health is more than 2.5% by weight, the blood pressure may rise rapidly above the reference value due to excessive blood circulation.
따라서, 전술한 바와 같은 각 원료들의 임계적 의의에 따르면, 상기 a) 단계에서는 여주 54.5중량% 내지 71.5중량%, 산약 8중량% 내지 11.5중량%, 상엽 4.5중량% 내지 7.4중량%, 양파 3.5중량% 내지 5.8중량%, 밀크씨슬 3.5중량% 내지 5.8중량%, 현미 1.5중량% 내지 2.5중량%, 서목태 1.5중량% 내지 2.5중량%, 솔잎 1.5중량% 내지 2.5중량%, 당귀 1.5중량% 내지 2.5중량%, 흑임자 1.5중량% 내지 2.5중량%, 건강 1.5중량% 내지 2.5중량%를 혼합하는게 바람직하다.Therefore, according to the critical significance of each raw material as described above, in step a), 54.5 wt% to 71.5 wt% of mallow, 8 wt% to 11.5 wt% of mung bean, 4.5 wt% to 7.4 wt% From 1.5% to 2.5% by weight of brown rice, from 1.5% to 2.5% by weight of pine needle, from 1.5% by weight to 2.5% by weight of Angelica seeds, from 3.5% to 5.8% By weight, from 1.5% by weight to 2.5% by weight of black tea, and from 1.5% by weight to 2.5% by weight of health.
b) 단계b) Step
상기 b) 단계는, 상엽 50 - 54중량% 및 오가피 46 - 50중량%에 물을 첨가하고, 70 - 80℃의 온도에서 2 - 3시간 열수추출 과정을 거친 후 추출액을 수득하는 단계로써,The step b) comprises adding water to 50 to 54% by weight of the top leaf and 46 to 50% by weight of the ophthalmic solution, subjecting the extract to hot water extraction at a temperature of 70 to 80 ° C for 2 to 3 hours,
상기 단계에서는 상엽 및 오가피를 열수추출하기 위해, 상기 상엽 50중량% 내지 54중량% 및 상기 오가피 46중량% 내지 50중량%에 물을 첨가하여 70℃ 내지 80℃의 온도에서 2시간 내지 3시간 열수추출 과정을 거쳐 추출액을 수득한다. 상기 물은 바람직하게는 상기 상엽 및 오가피의 중량% 대비 8배 내지 10배의 물을 첨가하는게 좋다.In the above step, water is added to 50% by weight to 54% by weight of the upper leaves and 46% to 50% by weight of the raw oak by hot water extraction to extract the upper leaves and the oak, and the water is heated for 2 to 3 hours at a temperature of 70 to 80 ° C. And an extract is obtained through an extraction process. The water is preferably added 8 to 10 times as much water as the weight of the upper leaves and the oak.
이때, 상기 물을 전술한 범위를 벗어나 첨가할 경우, 전체적인 식품 제조 과정에서 상엽 및 오가피의 유효성분이 충분히 우러나오지 않을 우려가 있으므로, 원료 대비 8배 내지 10배의 물을 첨가하는게 바람직하다.At this time, when the water is added outside the above-mentioned range, there is a possibility that the effective ingredient of the upper leaves and the oak is not sufficiently obtained in the whole food manufacturing process. Therefore, it is preferable to add water of 8 to 10 times as much as the raw material.
여기서, 상기 열수추출 과정은 통상의 열수추출법을 이용하여 실시할 수 있다.Here, the hot water extraction process can be performed using a conventional hot water extraction method.
상기 열수추출 과정은 통상의 경우보다 70℃ 내지 80℃의 온도 범위 내에서 항온(恒溫)을 유지하면서 수행하는 것이 특징인데, 이와 같은 항온에서의 온도를 일정하게 유지하기 위해서는 온풍, 열풍, 냉풍, 스팀 순환방식, 열교환기, 순환방식, 온돌방식 및 열기열선 순환 방식 중에서 어느 하나의 방식을 택하여 온도를 일정하게 유지할 수 있다.The hot water extraction process is performed while maintaining a constant temperature within a temperature range of 70 ° C. to 80 ° C. than usual. In order to keep the temperature constant at such a constant temperature, hot air, hot air, The temperature can be kept constant by adopting any one of the steam circulation system, the heat exchanger system, the circulation system, the ondol system, and the hot heat circulation system.
또, 항온 조건을 유지할 수 있도록 하기 위해 보온재, 단열재 등을 사용하여 내부의 온도가 외부의 영향을 받지 않도록 하는게 바람직하다. 이는 외부에서 올 수 있는 품질적 영향을 줄이고자 하는 것이다.In order to maintain the constant temperature condition, it is preferable to use a heat insulating material, a heat insulating material or the like so that the internal temperature is not influenced by the outside. This is intended to reduce the external impact of quality.
추가로, 상기 열수추출 과정을 실시할 때는 원료의 유효성분들이 균일하게 배합되어 추출될 수 있도록 주기적으로 내용물을 교반시킬 수도 있다.In addition, when the hot water extraction process is performed, the contents may be stirred periodically so that the active ingredients of the raw material are uniformly mixed and extracted.
c) 단계c) Step
상기 c) 단계는, b) 단계의 추출액을 여과하여 여액을 수득하는 단계로써,In the step c), the extract solution obtained in step b) is filtered to obtain a filtrate,
상기 단계에서는 추출액을 여과하여 원심분리법(원심력에 의해 액체중의 고체입자 또는 액체미립자를 분리하는 조작)으로 여액(濾液)을 수득할 수 있는데, 상기 원심분리법을 통해 미립자의 밀도차가 작은 성분까지 분리하여 유효성분이 함유를 극대화시켜, 기능성 효능을 더욱 향상시킬 수 있는 효과가 있다. 또한, 원심분리된 여액은 용해도 또는 흡수도가 높아져 제형을 용이하게 할 수 있다.In this step, a filtrate (filtrate) can be obtained by centrifugation (separation of solid particles or liquid fine particles in the liquid by centrifugal force) by filtration of the extract liquid. Through the centrifugation method, components having a small density difference of fine particles are separated Thereby maximizing the content of the active ingredient and further improving the functional efficacy. In addition, the centrifuged filtrate has a high solubility or a high degree of absorption and can facilitate the formulation.
d) 단계d) Step
상기 d) 단계는, c) 단계의 여액을 농도가 23brix 이상 이를때까지 농축하여 농축액을 수득하는 단계로써,The step d) comprises concentrating the filtrate of step c) until the concentration reaches 23 brix or more to obtain a concentrate,
상기 단계에서는 농축을 위한 유기용매를 추가로 사용할 수 있다. 유기용매로서 바람직하게는 알코올을 사용하는게 바람직하나, 이에 한정되지 않고 통상적으로 농축 과정을 수행할 때 사용되는 유기용매이면 본 발명에 적용하여 사용할 수 있다.In this step, an organic solvent for concentration can be further used. The organic solvent is preferably an alcohol, but is not limited thereto. Any organic solvent conventionally used in the concentration process may be used in the present invention.
한편, 상기 여액은 농도가 23brix 이상 이를때까지 농축하는게 바람직하다.Meanwhile, the filtrate is preferably concentrated until the concentration reaches 23 brix or more.
여기서, 상기 여액을 23brix 이상 이를때까지 농축하는 것은 점성이 높아지고, 또한 농도가 23brix 이상이 되면 충분한 유효성분의 배출이 이루어짐과 동시에 타 원료들과의 조화가 잘 이루어지게 된다. 이로써, 전술한 원료들의 성분이 한데 어우러져 기능적인 효과, 다시 말해 본 발명에서 달성하고자 하는 목적인 당뇨 개선 및 예방 효과를 상승시킬 수 있는 것이다.Here, when the filtrate is concentrated to 23 brix or more, the viscosity becomes high. When the concentration is more than 23 brix, the sufficient effective ingredient is discharged and the harmony with other materials is performed well. As a result, the components of the raw materials described above can be combined to enhance the functional effect, that is, the diabetic improvement and prevention effect, which is an object to be achieved in the present invention.
e) 단계e)
상기 e) 단계는, a) 단계의 혼합물과 d) 단계의 농축액을 1:0.4-0.6의 비율로 혼합하는 단계로써,The step e) comprises mixing the mixture of step a) and the concentrate of step d) in a ratio of 1: 0.4-0.6,
상기 a) 단계의 혼합물과 d) 단계의 농축액을 1:0.4-0.6의 비율로 혼합하여 최종적으로 본 발명에 따른 당뇨 예방 및 개선용 식품을 제조한다.The mixture of step a) and the concentrate of step d) are mixed at a ratio of 1: 0.4-0.6 to finally prepare a diabetic preventive and remedy food according to the present invention.
여기서, 상기 e) 단계를 거쳐 제조된 식품은 액상 형태로 이루어지며, 당 분야에서 통상적으로 사용되는 성분들을 적의 선정하여, 분말제, 환제, 정제, 캅셀제, 액제 및 현탁제 중 어느 하나의 제형으로 제형화 될 수 있다. 전술한 제형 이외에도 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있음은 물론이다.Here, the food prepared through the step (e) is in the form of a liquid, and the components commonly used in the art are selected and used as a powder, a pill, a tablet, a capsule, a solution or a suspension Can be formulated. It goes without saying that any other formulations conventionally produced in the art may be used in addition to the above-mentioned formulations.
이하, 실시예 및 시험예를 통하여 본 발명을 더욱 구체적으로 설명하기로 한다.Hereinafter, the present invention will be described in more detail with reference to examples and test examples.
[실시예 1][Example 1]
본 발명의 제조방법에 따라, 하기 표 1에 나타낸 원료들을 분말화하여 혼합하였다. 또한, 상엽 및 오가피의 추출액을 수득하기 위해, 상기 상엽 208g 및 오가피 192g에 물 1.6kg을 첨가하고, 75℃의 온도에서 3시간 동안 열수추출 과정을 거쳤다. 상기 열수추출 과정을 거친 추출액은 원심분리 하여 상등액 만을 취해, 상기 상등액을 농도가 23brix에 도달할 때까지 농축하여 농축액을 수득한 다음, 상기 혼합물과 상기 농축액을 1:0.5의 비율로 혼합하여 본 발명에 따른 식품을 제조하였다.According to the production method of the present invention, the raw materials shown in Table 1 below were powdered and mixed. In order to obtain the extract of the upper leaves and ogapi, 1.6 g of water was added to 208 g of the upper leaves and 192 g of ogapi and subjected to a hot water extraction process at a temperature of 75 캜 for 3 hours. The extract solution obtained by the hot water extraction process was centrifuged to take only the supernatant and the supernatant was concentrated until the concentration reached 23 brix to obtain a concentrate. The concentrate was mixed with the concentrate at a ratio of 1: 0.5, Was prepared.
[실시예 2][Example 2]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 2에 나타낸 바와 같이, 원료들의 함량만 달리하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1 except that the contents of the raw materials were different as shown in Table 2 below.
[실시예 3][Example 3]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 3에 나타낸 바와 같이, 원료들의 함량만 달리하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1 except that the contents of the raw materials were different as shown in Table 3 below.
[실시예 4][Example 4]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 4에 나타낸 바와 같이, 원료들의 함량만 달리하였다.Food was prepared by the same test conditions and manufacturing method as in Example 1 except that the contents of the raw materials were different as shown in Table 4 below.
[실시예 5][Example 5]
일반적으로 당뇨병 치료에 사용되는 양약인 글리퀴돈(gliquidone)을 입수하여 실시예 5에 적용하였다.Glyquidone, a commonly used medicament for the treatment of diabetes, was obtained and applied to Example 5.
[실시예 6][Example 6]
일반적으로 당뇨병 치료에 사용되는 한약재인 청심연자음(淸心蓮子飮)을 입수하여 실시예 6에 적용하였다.In general, the Chinese medicinal herb, which is used for the treatment of diabetes, was obtained and applied to Example 6.
[비교예 1][Comparative Example 1]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 5에 나타낸 바와 같이, 함유되는 원료 중 여주만을 제외하였다. 또한, 전체적인 중량이 실시예 1과 비슷해지도록 실시예 1에서 함유된 원료에 비해 약 2배 이상을 더 함유하였다.Food was prepared by the same test conditions and manufacturing method as in Example 1, except that only the raw material contained in the raw materials was excluded, as shown in Table 5 below. In addition, it contained about two times or more as much as the raw material contained in Example 1 so that the overall weight became similar to that of Example 1.
[비교예 2][Comparative Example 2]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 6에 나타낸 바와 같이, 함유되는 원료 중 산약만을 제외하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except that only the raw materials contained in the raw materials were included, as shown in Table 6 below.
[비교예 3][Comparative Example 3]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 7에 나타낸 바와 같이, 함유되는 원료 중 밀크씨슬만을 제외하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1 except that only the milk seeds contained in the raw materials contained were excluded, as shown in Table 7 below.
[비교예 4][Comparative Example 4]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 8에 나타낸 바와 같이, 함유되는 원료 중 여주 및 산약을 제외하였다. 또한, 전체적인 중량이 실시예 1과 비슷해지도록 실시예 1에서 함유된 원료에 비해 약 2배 이상을 더 함유하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except that the raw material and raw materials contained in the raw materials were excluded, as shown in Table 8 below. In addition, it contained about two times or more as much as the raw material contained in Example 1 so that the overall weight became similar to that of Example 1.
[비교예 5][Comparative Example 5]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 9에 나타낸 바와 같이, 함유되는 원료 중 여주 및 밀크씨슬을 제외하였다. 또한, 전체적인 중량이 실시예 1과 비슷해지도록 실시예 1에서 함유된 원료에 비해 약 2배 이상을 더 함유하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except for the raw material and the milk seeds contained in the raw materials as shown in Table 9 below. In addition, it contained about two times or more as much as the raw material contained in Example 1 so that the overall weight became similar to that of Example 1.
[비교예 6][Comparative Example 6]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 10에 나타낸 바와 같이, 함유되는 원료 중 산약 및 밀크씨슬을 제외하였다.Foods were prepared by the same test conditions and manufacturing method as in Example 1, except that the raw materials and milks seeds contained in the raw materials were excluded, as shown in Table 10 below.
[비교예 7][Comparative Example 7]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 11에 나타낸 바와 같이, 함유되는 원료 중 여주, 산약 및 밀크씨슬을 제외하였다. 또한, 전체적인 중량이 실시예 1과 비슷해지도록 실시예 1에서 함유된 원료에 비해 약 2배 이상을 더 함유하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except that the raw material, the liquorice, and the milk seeds contained therein were excluded, as shown in Table 11 below. In addition, it contained about two times or more as much as the raw material contained in Example 1 so that the overall weight became similar to that of Example 1.
[비교예 8][Comparative Example 8]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 12에 나타낸 바와 같이, 여주의 함량을 본 발명의 바람직한 중량비율을 벗어나 사용하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1 except that the content of Yeoju was used out of the preferable weight ratio of the present invention as shown in Table 12 below.
[비교예 9][Comparative Example 9]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 13에 나타낸 바와 같이, 산약의 함량을 본 발명의 바람직한 중량비율을 벗어나 사용하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except that the content of the liquorice was used outside the preferred weight ratio of the present invention, as shown in Table 13 below.
[비교예 10][Comparative Example 10]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 14에 나타낸 바와 같이, 상엽의 함량을 본 발명의 바람직한 중량비율을 벗어나 사용하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1, except that the contents of the upper leaves were used outside the preferred weight ratios of the present invention, as shown in Table 14 below.
[비교예 11][Comparative Example 11]
실시예 1과 동일한 시험조건과 제조방법에 의해 식품을 제조하되, 하기 표 15에 나타낸 바와 같이, 밀크씨슬의 함량을 본 발명의 바람직한 중량비율을 벗어나 사용하였다.The food was prepared by the same test conditions and manufacturing method as in Example 1 except that the content of milk seeds was used outside the preferred weight ratio of the present invention as shown in Table 15 below.
[시험예 1] 혈당 강하 효과 시험[Test Example 1] Test for hypoglycemic effect
혈당 강화 효과를 실험하기 위해, 제Ⅱ형 당뇨병(인슐린 비의존성 당뇨병) 모델 동물(rat, 마우스)을 설정하여, 마우스용 시판 사료(구성성분: 옥수수, 대두, 소맥, 우지, 조지방, 조회분, 조섬유, 칼슘, 인 등으로 구성, 조단백질 25% 이상)를 자유 급식의 방식으로 급여하였다.In order to test the blood glucose-enhancing effect, a model animal of the type II diabetes (non-insulin dependent diabetes mellitus) (rat, mouse) Crude protein, calcium, phosphorus, and crude protein of 25% or more) were fed in a free-of-feed manner.
여기서, 상기 제Ⅱ형 당뇨병에 대해 간단히 언급하자면, 제Ⅱ형 당뇨병은 확실한 기전이 알려져 있지는 않지만, 비만 등에 의해 말초 조직의 인슐린에 대한 저항성 증가가 발생하고, 이로 인해 과인슐린 혈증이 발생하게 된다. 제Ⅱ형 당뇨병 환자의 β세포는 혈당상승으로 인한 인슐린 분비에 대한 반응도가 감소되어, 소변으로 당이 배설되는 것을 인식하지 못하고 계속적으로 인슐린을 분비한다.Herein, the type II diabetes mellitus is briefly mentioned. Although a definite mechanism of type II diabetes is not known, obesity causes an increase in resistance to insulin in the peripheral tissues, resulting in hyperinsulinemia. [Beta] cells of type II diabetic patients do not recognize the excretion of glucose into the urine due to decreased responsiveness to insulin secretion due to elevated blood glucose, and secrete insulin continuously.
이러한 증상을 나타내는 KKAy마우스(제Ⅱ형 당뇨실험쥐) 360마리를 20마리씩 18개의 군(대조군, 시험군 1 내지 17)으로 나누었다. 대조군에는 생리 식염수만을 10㎖/㎏의 용량으로 투여하고, 시험군 1 내지 4에는 각각 실시예 1 내지 4에서 제조된 본 발명의 액상 형태의 식품을 0.5g/㎏/day의 용량으로 5주간 경구 투여하였다. 또한, 시험군 5에는 글리퀴돈(gliquidone)을 0.5g/㎏/day의 용량으로 5주간, 시험군 6에는 청심연자음(淸心蓮子飮)을 0.5g/㎏/day의 용량으로 5주간 투여하였다. 시험군 7 내지 13에는 각각 비교예 1 내지 7에서 제조된 액상 형태의 식품, 시험군 14 내지 17은 각각 비교예 8 내지 11에서 제조된 액상 형태의 식품을 0.5g/㎏/day의 용량으로 5주간 투여하였다.A total of 360 KKAy mice (type II diabetic rats) showing these symptoms were divided into 18 groups (control group, test group 1 to 17) in 20 animals. In the control group, only the physiological saline solution was administered at a dose of 10 ml / kg. In the test groups 1 to 4, the food of the liquid form of the present invention prepared in Examples 1 to 4 was administered orally at a dose of 0.5 g / . In the test group 5, gliquidone was administered at a dose of 0.5 g / kg / day for 5 weeks, and test group 6 was administered at a dose of 0.5 g / kg / day for 5 weeks Respectively. In the test groups 7 to 13, the food in the liquid form prepared in Comparative Examples 1 to 7 and in the test groups 14 to 17, the liquid foods prepared in Comparative Examples 8 to 11 were mixed at a rate of 0.5 g / kg / day Weekly.
대조군 및 시험군들에 대하여 각각, 약물 투여 전과 약물을 투여한 2시간 후에 마우스의 완와정맥총(Retro-Orbital plexus)으로부터 혈액을 채취하여 글루코스-미터(glucose-meter)를 이용하여 혈당을 측정하였다(혈당 단위:㎎/㎗).Blood was collected from the mouse's Retro-Orbital plexus before administration of the drug and 2 hours after administration of the drug, respectively, for the control and test groups, and glucose was measured using a glucose-meter Glucose unit: mg / dl).
측정 결과는 하기 표 16에 나타내었다.The measurement results are shown in Table 16 below.
상기 표 16에 따르면, 대조군과 비교할 때, 본 발명의 식품(시험군 1 내지 4)은 제Ⅱ형 당뇨병에 대하여 유의적인 혈당강하 효과를 나타낸다는 것을 확인할 수 있다.According to Table 16 above, it can be seen that the inventive foods (test groups 1 to 4) exhibit significant blood glucose lowering effects on type II diabetes when compared with the control group.
또한, 본 발명의 식품은 이미 효능이 입증되어 있는 대표적인 설포닐 우레아계 당뇨병 치료제인 글리퀴돈(시험군 5)과 당뇨병 치료용 한방제제인 청심연자음(시험군 6)과 비교할 때, 이들과 유사한 혈당강하 효과를 나타냄을 확인할 수 있다.In addition, the food of the present invention is similar to glycidon (test group 5), which is a representative sulfonylurea type diabetes treatment drug already proven efficacy, and the blue deep-eared consonant (test group 6), a herbal preparation for treating diabetes, It can be confirmed that the blood glucose lowering effect is exhibited.
또한, 본 발명에 따른 특정 원료를 특정 비율로 제조된 식품은, 이들 원료를 단독 사용하거나 또는 일부만 사용하는 경우(시험군 7 내지 13)나, 이 비율을 벗어나 제조된 경우(시험군 14 내지 17)에 비해, 혈당 강하 효과가 탁월함을 확인할 수 있다.The food prepared according to the present invention at specific ratios according to the present invention can be used in the case of using these raw materials singly or only partially (Test Groups 7 to 13) or when they are manufactured outside this ratio (Test Groups 14 to 17 ), It can be confirmed that the blood glucose lowering effect is excellent.
[시험예 2] 급성 독성 시험[Test Example 2] Acute toxicity test
실험동물을 이용하여 본 발명의 식품에 대해 급성독성의 기준치인 LD50치를 구하였다.The LD 50 value of acute toxicity was determined for the food of the present invention using an experimental animal.
실험동물로는 ICR 마우스 100마리를 사용하였으며, 실험에 앞서 1일간 절식시켰다. 이들 마우스를 20마리씩 5개군(가 내지 마군)으로 나누었다. 가군은 생리 식염수 10㎖/㎏만을 투여하여 대조군으로 사용하였으며, 나군에는 실시예 1에서 제조된 본 발명의 식품을 10g/㎏/day의 용량으로 투여하였다. 다군에는 실시예 1의 식품을 30g/㎏/day의 용량으로, 라군에는 실시예 1의 식품을 60g/㎏/day의 용량으로, 마군에는 실시예 1의 식품을 100g/㎏/day의 용량으로 투여하였다.As an experimental animal, 100 ICR mice were used and fasted for 1 day prior to the experiment. These mice were divided into 5 groups (20 to 20 mice). As a control group, only 10 ml / kg of physiological saline solution was administered to the dogs, and the food of the present invention prepared in Example 1 was administered at a dose of 10 g / kg / day. The food of Example 1 was used at a dose of 30 g / kg / day, the lagoon at a dose of 60 g / kg / day, the food of Example 1 at a dose of 100 g / kg / day .
실험 결과는 하기 표 17에 나타내었다.The experimental results are shown in Table 17 below.
(투여량)Administered ingredient
(Dose)
사망 동물 수After 24 hours
Number of dead animals
(10㎖/㎏)Saline solution
(10 ml / kg)
(10g/㎏/day)The food of the present invention
(10 g / kg / day)
(30g/㎏/day)The food of the present invention
(30 g / kg / day)
(60g/㎏/day)The food of the present invention
(60 g / kg / day)
(100g/㎏/day)The food of the present invention
(100 g / kg / day)
상기 표 17에 따르면, 나 내지 마군의 동물에는 해당하는 용량의 본 발명의 식품을 생리식염수에 용해시켜 경구 투여하였다. 경구 투여한지 24시간 후에 각 군 별로 사망한 동물의 수를 확인하였다. 실험 결과, 나군과 다군에서는 사망한 실험동물이 없었고, 라군에서는 1마리, 마군에서는 2마리의 실험동물이 사망하였다.According to Table 17, the food of the present invention was dissolved or dissolved in physiological saline and administered orally to the animals of Groups I and II. Twenty-four hours after oral administration, the number of dead animals in each group was determined. As a result, there were no dead animals in Nago and Da - gun, 1 animal in lagoon and 2 animals in marine.
한편, LD50을 구하기 위해서는 실험동물의 50%, 즉 실험동물인 마우스 10마리가 사망하는 용량으로 증량투여 하여야 하나, 본 발명의 식품은 물에 잘 용해되지 않는 성질이 있으며, 100g/㎏이상을 용해시키려면 약물의 부피가 너무 커져 실험동물에 투여하는데 문제점이 있다.In order to obtain the LD 50 , 50% of the experimental animals, that is, 10 mice, which are experimental animals, should be dosed at an increased dose, but the food of the present invention is not soluble in water, To dissolve the drug, the volume of the drug is too large to be administered to an experimental animal.
이러한 결과로 보건데, 본 발명의 식품을 투여한 나, 다, 라 및 마군에서 저혈당 등의 부작용이 초래된 실험동물은 없었으며 LD50은 100g/㎏ 이상인 것으로 추정된다.As a result, there was no experimental animal in which the side effects such as hypoglycemia were caused in the food of the present invention, the LD 50 was estimated to be 100 g / kg or more.
100g/㎏/day를 투여하는 것은 한국인의 평균 체중인 70kg으로 환산 시, 본 발명의 식품을 1일에 7kg이상 투여하는 효과를 나타내므로, 본 발명의 식품은 실질적으로 독성이 거의 없는 안전한 식품인 것으로 판단된다.Since the administration of 100 g / kg / day has the effect of administering the food of the present invention at least 7 kg per day when converted to 70 kg, which is the average weight of Korean, the food of the present invention is a safe food having substantially no toxicity .
Claims (4)
b) 상엽 50 - 54중량% 및 오가피 46 - 50중량%에 물을 첨가하고, 70 - 80℃의 온도에서 2 - 3시간 열수추출 과정을 거친 후 추출액을 수득하는 단계;
c) 상기 b) 단계의 추출액을 여과하여 여액을 수득하는 단계;
d) 상기 c) 단계의 여액을 농도가 23brix 이상 이를때까지 농축하여 농축액을 수득하는 단계;
e) 상기 a) 단계의 혼합물과 d) 단계의 농축액을 1:0.4-0.6의 비율로 혼합하는 단계로 이루어지는 것을 특징으로 하는 당뇨 예방 및 개선용 식품의 제조방법.a) Leeks 54.5 - 71.5% by weight, Acacia 8.0 - 11.5% by weight, Upper leaf 4.5 - 7.4% by weight, Onion 1.5 - 2.5% by weight, Milk Seeds 3.5 - 5.8% by weight, Brown rice 1.5 - 2.5% Preparing 1.5 to 2.5 wt% of pine needle, 1.5 to 2.5 wt% of Angelica keiskei, 1.5 to 2.5 wt% of blackberry, and 1.5 to 2.5 wt% of health to prepare a mixture;
b) adding water to 50 to 54% by weight of the upper leaves and 46 to 50% by weight of the oak, extracting the extract after 2 to 3 hours of hot water extraction at a temperature of 70 to 80 ° C;
c) filtering the extract of step b) to obtain a filtrate;
d) concentrating the filtrate of step c) until the concentration reaches 23 brix or more to obtain a concentrate;
e) mixing the mixture of step a) and the concentrate of step d) in a ratio of 1: 0.4-0.6.
상기 c) 단계의 여액은 b) 단계의 추출액을 원심분리하여 상등액을 수득한 다음, 상기 상등액을 여과하여 수득된 것임을 특징으로 하는 당뇨 예방 및 개선용 식품의 제조방법.The method according to claim 1,
Wherein the filtrate of step c) is obtained by centrifuging the extract of step b) to obtain a supernatant, and then filtering the supernatant.
상기 a) 단계의 현미는 현미배아 또는 호분층 중 어느 하나 또는 2가지 모두가 혼합된 것임을 특징으로 하는 당뇨 예방 및 개선용 식품의 제조방법.The method according to claim 1,
Wherein the brown rice of step (a) is a mixture of any one or both of a brown rice embryo or a colony layer.
상기 e) 단계를 거친 혼합물은 분말제, 환제, 정제, 캅셀제, 액제 및 현탁제 형태 중 어느 하나의 제형으로 제형화 되는 것을 특징으로 하는 당뇨 예방 및 개선용 식품의 제조방법.The method according to claim 1,
Wherein the mixture obtained through step e) is formulated into any one of powder, pills, tablets, capsules, liquids and suspensions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160123163A KR101850955B1 (en) | 2016-09-26 | 2016-09-26 | Method of producing a food for preventing and improving diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160123163A KR101850955B1 (en) | 2016-09-26 | 2016-09-26 | Method of producing a food for preventing and improving diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180033781A true KR20180033781A (en) | 2018-04-04 |
KR101850955B1 KR101850955B1 (en) | 2018-04-20 |
Family
ID=61975535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160123163A KR101850955B1 (en) | 2016-09-26 | 2016-09-26 | Method of producing a food for preventing and improving diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101850955B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200076186A (en) * | 2018-12-19 | 2020-06-29 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus |
EP3744338A1 (en) | 2019-05-30 | 2020-12-02 | Ugur Yem Katki Maddeleri San. ve Tic. Ltd. Sti. | Medical uses of red pine resin and dosage forms therof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005229008B2 (en) * | 2004-03-23 | 2011-03-24 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
KR100956474B1 (en) * | 2009-10-08 | 2010-05-07 | 함양영농조합법인 | Manufacturing method for balsam pear pill |
-
2016
- 2016-09-26 KR KR1020160123163A patent/KR101850955B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200076186A (en) * | 2018-12-19 | 2020-06-29 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus |
EP3744338A1 (en) | 2019-05-30 | 2020-12-02 | Ugur Yem Katki Maddeleri San. ve Tic. Ltd. Sti. | Medical uses of red pine resin and dosage forms therof |
Also Published As
Publication number | Publication date |
---|---|
KR101850955B1 (en) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (en) | Composition for anti-obesity | |
CN102727586A (en) | Composition for preventing and treating diabetes | |
JP6463504B2 (en) | Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement | |
KR20180137174A (en) | Health supplementing food for enhancing hair restoration, alleviating and improving hair loss | |
KR20070000573A (en) | The heath food having an effect on dropping blood sugar and constipation | |
KR101850955B1 (en) | Method of producing a food for preventing and improving diabetes | |
CN107613998A (en) | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient | |
KR101995281B1 (en) | A composition comprising extract of ligularia fischeri and momordica charantia for preventing and treating and manufacturing method thereof | |
CN103719864A (en) | Blood glucose-reducing natto combined capsule and preparation method thereof | |
KR100697184B1 (en) | A functional food for a ginseng and mulberry and banaba and the producing method therof | |
KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
CN101336965A (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
CN107712890A (en) | A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof | |
KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
KR20130041494A (en) | The composition for treating diabetes | |
KR101528557B1 (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
CN110679685A (en) | Novel probiotic healthy tea for treating hypertension and preparation method thereof | |
CN104324278A (en) | Production method of antiobesity drug and antiobesity granules | |
KR101118047B1 (en) | An oriental drink comprising a phyllostachys bambusoides, a barley sprout, a yacon strawberry and a mulberry leaves | |
CN110226721A (en) | A kind of composition with auxiliary hyperglycemic function | |
KR102368446B1 (en) | Composition for preventing or treating diabetes | |
KR20140064067A (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of zanthoxylum piperitum and piper nigrum | |
KR100679698B1 (en) | An extract of Pterocarya paliurus with blood sugar level-lowering activity and functional food comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |